latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/us-court-rules-in-favor-of-bio-rad-in-patent-case-against-10x-genomics-59747242 content esgSubNav
In This List

US court rules in favor of Bio-Rad in patent case against 10x Genomics

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

US court rules in favor of Bio-Rad in patent case against 10x Genomics

A U.S. court upheld a ruling in favor of Bio-Rad Laboratories Inc. in a patent infringement case against 10x Genomics Inc.

The U.S. Court of Appeals for the Federal Circuit supported the District Court's finding that Pleasanton, Calif.-based 10x Genomics willfully infringed a patent exclusively licensed to Hercules, Calif.-based Bio-Rad from the University of Chicago.

The Court of Appeals also upheld the lower court's November 2018 decision to award $23.9 million in damages to Bio-Rad and to order 10x Genomics, a life science technology company, to put into escrow a 15% royalty on past and future sales of three genomics products that were found to have infringed the patent. A permanent injunction against the products was also upheld.

However, the appellate court withdrew the District Court's injunction relating to 10x Genomics' Linked-Read and CNV product lines, and reversed a decision on infringement of Bio-Rad's two other patent claims. Bio-Rad said it believes these developments will not have a material impact on the trial's overall result and said it is evaluating options for further review.

Bio-Rad offers products for life science research and clinical diagnostic markets.